Title : Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.

Pub. Date : 2014 Apr

PMID : 24481648






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ponatinib, a multi-targeted TKI, inhibits the activity of BCR-ABL with very high potency and broad specificity, including the T315I mutation which confers resistance to other TKIs. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens